Certis Oncology Solutions – a precision oncology and translational science company focused on combining AI-directed drug development with advanced functional testing – recently announced that it raised $10 million in a Series C funding round, raising the total to $42 million. The company also named John R. Tozzi Chairman of its Board of Directors.
Certis Oncology Solutions is a life science technology company focused on realizing the promise of precision oncology. And the company’s product is Oncology Intelligence — a highly predictive therapeutic response data derived from advanced models of cancer. The company partners with physician-scientists and industry researchers to expand access to precision oncology and close the problematic translation gap between preclinical studies and clinical trials.
KEY QUOTES:
“We welcome John’s leadership and this additional investment at this critical inflection point for our company. Now serving more than 120 oncology therapeutics companies, we have established the necessary business traction to see a clear path to profitable growth. At the same time, ongoing validation studies give us great confidence that our proprietary CertisAI predictive oncology platform soon will be able to deliver truly personalized cancer treatment at scale.”
– Peter Elman, President and CEO of Certis
“Our investors are passionate about the company’s patient-focused mission and 100% behind its three-pronged strategy for creating shareholder value: building a best-in-class bank of advanced tumor models for cancer research, developing disruptive AI-based intellectual property, and generating services revenue from very specialized contract research to help fund R&D.”
– New Certis Board of Directors Chairman John Tozzi – who also serves as the Certis Chairman of the Executive and Finance Committees and led the company’s last two internal funding rounds along with this most recent raise in which 94% of the company’s top 50 investors participated; In 1982 Tozzi founded Cambridge Investments LLC, an investment management firm, and continues to serve as its CEO and CIO.
